| L1210 |
IC50 |
= |
12.0 |
ug.mL-1 |
Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse. |
CHEMBL1125887 |
| NON-PROTEIN TARGET |
EC90 |
= |
2.3 |
uM |
Effective concentration required to reduce cytopathic effects caused by bovine viral diarrhea virus (BVDV) in MDBK cells by 90% |
CHEMBL1141159 |
| NON-PROTEIN TARGET |
CC50 |
> |
100000.0 |
nM |
Cytotoxic concentration against bovine viral diarrhea virus (BVDV) in MDBK cells |
CHEMBL1141159 |
| Huh-7 |
EC90 |
= |
19.0 |
uM |
Effective concentration required to reduce HCV replication RNA levels in Huh7 cells by 90% determined by HCV replicon assay |
CHEMBL1141159 |
| Huh-7 |
CC50 |
> |
100000.0 |
nM |
Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay |
CHEMBL1141159 |
| Rattus norvegicus |
Cmax |
= |
23790.09 |
nM |
Cmax in jugular vein cannulated Sprague-Dawley rat at 100 mg/kg, po administered as prodrug |
CHEMBL1137330 |
| Rattus norvegicus |
T1/2 |
= |
7.1 |
hr |
Terminal half life in jugular vein cannulated Sprague-Dawley rat at 100 mg/kg, po administered as prodrug |
CHEMBL1137330 |
| Rattus norvegicus |
Tmax |
= |
2.0 |
hr |
Tmax in jugular vein cannulated Sprague-Dawley rat at 100 mg/kg, po administered as prodrug |
CHEMBL1137330 |
| Rattus norvegicus |
AUC |
= |
30000.0 |
ng.hr.mL-1 |
AUC(0-t) in jugular vein cannulated Sprague-Dawley rat at 100 mg/kg, po administered as prodrug |
CHEMBL1137330 |
| Rattus norvegicus |
F |
= |
33.6 |
% |
Apparent oral bioavailability in jugular vein cannulated Sprague-Dawley rat at 100 mg/kg, po administered as prodrug |
CHEMBL1137330 |
| No relevant target |
Solubility |
= |
32000.0 |
ug.mL-1 |
Aqueous solubility of the compound |
CHEMBL1137330 |
| No relevant target |
LogP |
= |
-0.965 |
|
Distribution coefficient, log P of the compound |
CHEMBL1137330 |
| Plasma |
PPB |
= |
5.0 |
% |
Protein binding in rat plasma at 20 uM |
CHEMBL1137330 |
| Rattus norvegicus |
Cmax |
= |
293877.55 |
nM |
Cmax in Sprague-Dawley rat after 15 days at 60 mg/kg/day, iv |
CHEMBL1137330 |
| Rattus norvegicus |
AUC |
= |
74400.0 |
ng.hr.mL-1 |
AUC in Sprague-Dawley rat after 15 days at 60 mg/kg/day, iv |
CHEMBL1137330 |
| No relevant target |
Stability |
|
|
% |
Chemical stability at pH 1.2 |
CHEMBL1137330 |
| No relevant target |
Stability |
|
|
% |
Chemical stability at pH 4.5 |
CHEMBL1137330 |
| No relevant target |
Stability |
|
|
% |
Chemical stability at pH 7.2 |
CHEMBL1137330 |
| Deoxycytidine kinase |
Km |
= |
914000.0 |
nM |
Activity of human dCK expressed in HepG2 cells assessed as phosphorylation by coupled enzyme assay |
CHEMBL1142170 |
| Deoxycytidine kinase |
Kcat/Km |
= |
1.2e-05 |
/uM/s |
Ratio of Kcat to Km for human dCK expressed in HepG2 cells |
CHEMBL1142170 |
| Deoxycytidine kinase |
Kcat |
= |
0.011 |
/s |
Activity of human dCK expressed in HepG2 cells assessed as phosphorylation by coupled enzyme assay |
CHEMBL1142170 |
| Uridine-cytidine kinase 1 |
Activity |
|
|
|
Activity of human UCK1 expressed in Huh7 cells assessed as phosphorylation by coupled enzyme assay |
CHEMBL1142170 |
| Uridine-cytidine kinase 1 |
Activity |
|
|
|
Ratio of Kcat to Km for UCK1 activity expressed in Huh7 cells |
CHEMBL1142170 |
| Hepatitis C virus |
IC50 |
= |
1230.0 |
nM |
Antiviral activity against HCV 1b replicon in human 2209-23 cells |
CHEMBL1139169 |
| ADMET |
CC50 |
> |
33000.0 |
nM |
Cytotoxicity against human 2209-23 cells |
CHEMBL1139169 |
| ADMET |
CT50 |
> |
100.0 |
uM |
Cytostatic activity against human 2209-23 cells |
CHEMBL1139169 |
| Hepatitis C virus |
EC50 |
= |
3500.0 |
nM |
Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay |
CHEMBL1139357 |
| Hepatitis C virus |
EC90 |
= |
11.0 |
uM |
Antiviral activity against HCV in human Huh7 cells assessed as reduction of viral level after 5 days by RNA subgenomic replicon assay |
CHEMBL1139357 |
| ADMET |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against human Huh7 cells assessed as rRNA level after 5 days |
CHEMBL1139357 |
| Unchecked |
Activity |
= |
2.0 |
uM |
Inhibition of HCV NS5B polymerase by cell-based assay |
CHEMBL1153533 |
| Cytidine deaminase |
Kcat |
= |
0.18 |
/s |
Activity of cloned cytidine deaminase in human HuH7 cells at 4 mM by spectrophotometric analysis |
CHEMBL1152990 |
| Cytidine deaminase |
Km |
= |
3100000.0 |
nM |
Activity of cloned cytidine deaminase in human HuH7 cells at 4 mM by spectrophotometric analysis |
CHEMBL1152990 |
| Cytidine deaminase |
Kcat/Km |
= |
5.8e-05 |
/uM/s |
Ratio of Kcat to Km for cloned cytidine deaminase in human HuH7 cells by spectrophotometric analysis |
CHEMBL1152990 |
| Hepatitis C virus |
EC50 |
= |
1230.0 |
nM |
Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay |
CHEMBL1255315 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HuH7 cells |
CHEMBL1255315 |
| Hepatitis C virus |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC50 |
= |
2200.0 |
nM |
Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC90 |
= |
9.0 |
uM |
Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC90 |
= |
6.1 |
uM |
Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC90 |
= |
8.9 |
uM |
Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| ADMET |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human RP7 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay |
CHEMBL1275532 |
| ADMET |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human NTZ-11 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay |
CHEMBL1275532 |
| ADMET |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human TIZ-9 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay |
CHEMBL1275532 |
| Unchecked |
Ratio CC50/EC50 |
> |
150.0 |
|
Selectivity Index, ratio of CC50 for RP7 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in RP7 replicon cell |
CHEMBL1275532 |
| Unchecked |
Ratio CC50/EC50 |
> |
158.0 |
|
Selectivity Index, ratio of CC50 for NTZ-11 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in NTZ-11 replicon cell |
CHEMBL1275532 |
| Unchecked |
Ratio CC50/EC50 |
> |
136.0 |
|
Selectivity Index, ratio of CC50 for TIZ-9 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in TIZ-9 replicon cell |
CHEMBL1275532 |
| Hepatitis C virus |
Activity |
= |
10.0 |
% |
Antiviral activity against HCV genotype 1b obtained from RP7 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 10 uM after 10 to 14 days in presence of 125 ug/ml G418 |
CHEMBL1275532 |
| Hepatitis C virus |
Activity |
= |
13.0 |
% |
Antiviral activity against HCV genotype 1b obtained from NTZ-11 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 10 uM after 10 to 14 days in presence of 125 ug/ml G418 |
CHEMBL1275532 |
| Hepatitis C virus |
Activity |
= |
9.0 |
% |
Antiviral activity against HCV genotype 1b obtained from TIZ-9 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 10 uM after 10 to 14 days in presence of 125 ug/ml G418 |
CHEMBL1275532 |
| Hepatitis C virus |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Hepatitis C virus subtype 1b with adaptive mutations of E1202G, T1280I, K1846T in NS5B polymerase infected in human HuH7 cells assessed as inhibition of viral replication after 3 days by luciferase assay |
CHEMBL1275401 |
| ADMET |
CC50 |
> |
98400.0 |
nM |
Cytotoxicity against human HuH7 cells expressing CMV-Luc after 3 days by luciferase assay |
CHEMBL1275401 |
| MT4 |
CC50 |
> |
98400.0 |
nM |
Cytotoxicity against human MT4 cells expressing LTR-Luc after 3 days by luciferase assay |
CHEMBL1275401 |
| Hepatitis C virus |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
480.0 |
nM |
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
230.0 |
nM |
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
620.0 |
nM |
Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
1.0 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus genotype 1a H77 in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
1.0 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus genotype 2a JFH1 in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
0.4 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
0.2 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
2.0 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
0.5 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
1.0 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 with NS5B polymerase L419I mutant in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
1.0 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 with NS5B polymerase I482L mutant in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
FC |
= |
1.0 |
|
Ratio of EC50 for wild-type Hepatitis C virus isolate Con1 to EC50 for Hepatitis C virus isolate Con1 with NS5B polymerase L419I and I482L mutant in human Huh7.5 cells by hRLuc reporter gene assay |
CHEMBL1629557 |
| Hepatitis C virus |
EC50 |
= |
110.0 |
nM |
Antiviral activity against compound-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
210.0 |
nM |
Antiviral activity against cyclosporine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
30150.0 |
nM |
Antiviral activity against 2'-C-methyl-2'-fluoro-cytidine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
1160.0 |
nM |
Antiviral activity against R479-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
40.0 |
nM |
Antiviral activity against BILN 2061-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
1010.0 |
nM |
Antiviral activity against VX 950-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
410.0 |
nM |
Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
EC50 |
= |
700.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis |
CHEMBL1671625 |
| Hepatitis C virus |
EC50 |
= |
700.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis |
CHEMBL1671625 |
| Hepatitis C virus |
EC50 |
= |
400.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis |
CHEMBL1671625 |
| Hepatitis C virus |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay |
CHEMBL1671625 |
| ADMET |
CC50 |
> |
33000.0 |
nM |
Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay |
CHEMBL1671625 |
| ADMET |
CC50 |
> |
33000.0 |
nM |
Cytotoxicity against human HuH6 cells after 3 days by MTT assay |
CHEMBL1671625 |
| ADMET |
CC50 |
= |
25000.0 |
nM |
Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay |
CHEMBL1671625 |
| ADMET |
CC50 |
> |
33000.0 |
nM |
Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay |
CHEMBL1671625 |
| Hepatitis C virus |
EC50 |
= |
1143.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis |
CHEMBL1687718 |
| Hepatitis C virus |
EC50 |
= |
1623.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis |
CHEMBL1687718 |
| Hepatitis C virus |
Ratio IC50 |
= |
1.0 |
|
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis relative to control |
CHEMBL1687718 |
| Hepatitis C virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days |
CHEMBL1795274 |
| Hepatitis C virus |
EC90 |
= |
8.2 |
uM |
Antiviral activity against HCV1a infected in human HuH7 cells expressing E2 glycoprotein assessed as inhibition of viral RNA replication after 5 days |
CHEMBL1795274 |
| Huh-7 |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HuH7 cells expressing E2 glycoprotein assessed as reduction of rRNA level after 5 days |
CHEMBL1795274 |
| Unchecked |
Ratio CC50/EC50 |
> |
272.0 |
|
Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for HCV 1a |
CHEMBL1795274 |
| Hepatitis C virus |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay |
CHEMBL1828535 |
| Huh-7 |
CC50 |
> |
33000.0 |
nM |
Cytotoxicity against human HuH7 cells after 72 hrs |
CHEMBL1828535 |
| Human immunodeficiency virus 1 |
Inhibition |
|
|
% |
Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days |
CHEMBL1828535 |
| BHK-21 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay |
CHEMBL1938334 |
| Reovirus sp. |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Reovirus type-1 3651 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL1938334 |
| Hepatitis C virus |
EC50 |
= |
2800.0 |
nM |
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR |
CHEMBL1949592 |
| Hepatitis C virus |
EC90 |
= |
9.6 |
uM |
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR |
CHEMBL1949592 |
| Huh-7 |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs |
CHEMBL1949592 |
| Human immunodeficiency virus 1 |
EC50 |
= |
47500.0 |
nM |
Antiviral activity against HIV1 LAV1 infected in PHA-stimulated human PBMC assessed as reduction in RT activity after 6 days by micromethod-based beta scintillation counting |
CHEMBL1949592 |
| Human immunodeficiency virus 1 |
EC90 |
= |
100.0 |
uM |
Antiviral activity against HIV1 LAV1 infected in PHA-stimulated human PBMC assessed as reduction in RT activity after 6 days by micromethod-based beta scintillation counting |
CHEMBL1949592 |
| PBMC |
IC50 |
= |
47400.0 |
nM |
Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method |
CHEMBL1949592 |
| CCRF-CEM |
IC50 |
= |
54400.0 |
nM |
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method |
CHEMBL1949592 |
| Vero |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis |
CHEMBL1949592 |
| Human coxsackievirus B3 |
EC50 |
= |
94000.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay |
CHEMBL2010699 |
| Human coxsackievirus B3 |
EC90 |
= |
179.0 |
uM |
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition virus-induced cell death by MTS assay |
CHEMBL2010699 |
| Vero |
CC50 |
|
|
|
Cytotoxicity against african green monkey Vero cells assessed as inhibition of host metabolism by MTS assay |
CHEMBL2010699 |
| Unchecked |
Ratio CC50/EC50 |
|
|
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Coxsackievirus B3 |
CHEMBL2010699 |
| Hepatitis C virus |
EC50 |
= |
4070.0 |
nM |
Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs |
CHEMBL2029282 |
| Huh-7 |
CC50 |
> |
89000.0 |
nM |
Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay |
CHEMBL2029282 |
| Hepatitis C virus |
IC50 |
= |
730.0 |
nM |
Inhibition of HCV genotype 1b NS5B after 90 mins |
CHEMBL2029282 |
| BHK-21 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK21 cells by MTT assay |
CHEMBL2034874 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL2034874 |
| Huh-7 |
CC50 |
> |
98000.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 3 days by BrdU incorporation assay |
CHEMBL3120160 |
| Hepatitis C virus |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay |
CHEMBL3120160 |
| Hepatitis C virus |
EC50 |
= |
1600.0 |
nM |
Antiviral activity against Hepatitis C virus assessed as inhibition of viral infection by RNA replicon assay |
CHEMBL3120115 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL3352401 |
| NON-PROTEIN TARGET |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Simian virus 12 3651 (ATCC VR- 214) infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL3352401 |
| NON-PROTEIN TARGET |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against HCV1a assessed as inhibition of viral replication by cell based 384 well format assay |
CHEMBL3352022 |
| NON-PROTEIN TARGET |
EC50 |
= |
2800.0 |
nM |
Antiviral activity against HCV1b assessed as inhibition of viral replication by cell based 384 well format assay |
CHEMBL3352022 |
| Unchecked |
IC50 |
= |
1670.0 |
nM |
Inhibition of HCV1b NS5B polymerase |
CHEMBL3352022 |
| NON-PROTEIN TARGET |
EC50 |
= |
2800.0 |
nM |
Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay |
CHEMBL3396979 |
| NON-PROTEIN TARGET |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay |
CHEMBL3396979 |
| Unchecked |
IC50 |
= |
1700.0 |
nM |
Inhibition of HCV genotype 1b NS5B RNA dependent RNA polymerase assessed as reduction in triphosphate activity |
CHEMBL3396979 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against hamster BHK21 cells assessed as cell viability after 72 hrs by MTT method |
CHEMBL3421576 |
| NON-PROTEIN TARGET |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against Reovirus 1 infected in hamster BHK21 cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method |
CHEMBL3421576 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3616436 |
| NON-PROTEIN TARGET |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Reovirus type-1 ATCC VR-214 infected in BHK cells assessed as protection against virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3616436 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining |
CHEMBL3616436 |
| Human coxsackievirus B5 |
EC50 |
= |
18000.0 |
nM |
Antiviral activity against Human coxsackievirus B5 ATCC VR-29 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining |
CHEMBL3616436 |
| Human poliovirus 1 |
EC50 |
= |
7300.0 |
nM |
Antiviral activity against Poliovirus type 1 ATCC VR-1562 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 2 days by crystal violet staining |
CHEMBL3616436 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay |
CHEMBL3734708 |
| ADMET |
CC50 |
= |
16000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734708 |
| NON-PROTEIN TARGET |
EC50 |
= |
18000.0 |
nM |
Antiviral activity against Norovirus infected in HG23 cells assessed as decrease in viral RNA level by qRT-PCR analysis |
CHEMBL3745643 |
| ADMET |
CC50 |
= |
94750.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by MTS assay |
CHEMBL3792388 |
| Unchecked |
Ratio CC50/EC50 |
> |
8.5 |
|
Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for Dengue virus 2 DN454009A infected in human HuH7 cells |
CHEMBL3792388 |
| Dengue virus 2 |
EC50 |
= |
11200.0 |
nM |
Antiviral activity against Dengue virus 2 DN454009A infected in human HuH7 cells assessed as inhibition of viral RNA level measured 72 hrs post infection by qRT-PCR method |
CHEMBL3792388 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3808296 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| NON-PROTEIN TARGET |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3808296 |
| Human coxsackievirus B2 |
EC50 |
|
|
|
Antiviral activity against CVB-2 infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Human poliovirus 1 strain Sabin |
EC50 |
|
|
|
Antiviral activity against Human poliovirus 1 strain Sabin infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Respiratory syncytial virus |
EC50 |
|
|
|
Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Vesicular stomatitis virus |
EC50 |
|
|
|
Antiviral activity against Vesicular stomatitis virus Indiana infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Vaccinia virus |
EC50 |
|
|
|
Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Unchecked |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against HCV genotype 1b harboring wild type NS5B infected in human HuH7 cells assessed as inhibition of viral RNA replication after 5 days by RT-PCR method |
CHEMBL4014354 |
| Unchecked |
EC90 |
= |
6.5 |
uM |
Antiviral activity against HCV genotype 1b harboring wild type NS5B infected in human HuH7 cells assessed as inhibition of viral RNA replication after 5 days by RT-PCR method |
CHEMBL4014354 |
| Huh-7 |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay |
CHEMBL4014354 |
| PBMC |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay |
CHEMBL4014354 |
| CCRF-CEM |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay |
CHEMBL4014354 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay |
CHEMBL4014354 |
| Heat shock factor protein 1 |
Activity |
|
|
|
Activation of HSF-1 in human HG23 cells transfected with human norovirus after 72 hrs by dual-luciferase reporter gene assay |
CHEMBL4311988 |
| Unchecked |
Activity |
= |
78.5 |
% |
Cytotoxicity against human HG23 cells assessed as cell viability at 10 uM after 3 days by tetrazolium dye based assay relative to control |
CHEMBL4311988 |
| Unchecked |
CC50 |
= |
12200.0 |
nM |
Cytotoxicity against human HG23 cells assessed as reduction in cell viability after 3 days by tetrazolium dye based assay |
CHEMBL4311988 |
| Norovirus |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against human norovirus infected in human HG23 cells assessed as inhibition of viral replication after 3 days by qRT-PCR analysis |
CHEMBL4311988 |
| ADMET |
Ratio CC50/EC50 |
= |
3.1 |
|
Therapeutic index, ratio of CC50 for cytotoxicity against human HG23 cells harboring human norovirus replicons to EC50 for antiviral activity against norovirus infected in human HG23 cells |
CHEMBL4311988 |
| Norovirus |
EC50 |
= |
4800.0 |
nM |
Antiviral activity against human norovirus infected in HG23 cells assessed as inhibition of neomycin phosphotransferase protein expression after 3 days by Western blot analysis |
CHEMBL4311988 |
| Norovirus |
Activity |
= |
24.8 |
% |
Antiviral activity against human norovirus infected in human HG23 cells assessed as inhibition of viral replication at 10 uM after 3 days by qRT-PCR analysis relative to control |
CHEMBL4311988 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
EC50 |
= |
2800.0 |
nM |
Inhibition of NS5B polymerase in wild type HCV genotype 1b infected in human Huh7 replicon cells after 5 days by RT-PCR assay |
CHEMBL4411318 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
EC90 |
= |
9.9 |
uM |
Inhibition of NS5B polymerase in wild type HCV genotype 1b infected in human Huh7 replicon cells after 5 days by RT-PCR assay |
CHEMBL4411318 |
| Huh-7 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay |
CHEMBL4411318 |
| PBMC |
CC50 |
= |
60000.0 |
nM |
Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay |
CHEMBL4411318 |
| CCRF-CEM |
CC50 |
= |
22000.0 |
nM |
Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay |
CHEMBL4411318 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay |
CHEMBL4411318 |
| Replicase polyprotein 1ab |
Inhibition |
= |
14.92 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
-0.08 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
-0.08 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| Unchecked |
EC50 |
= |
8200.0 |
nM |
Antiviral activity against human Norovirus |
CHEMBL4680252 |
| Unchecked |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against murine Norovirus infected in mouse RAW264.7 cells assessed as reduction in virus-induced cytopathic effect incubated for 3 days by MTS assay |
CHEMBL4680252 |
| Unchecked |
EC50 |
= |
30.0 |
nM |
Antiviral activity against human Norovirus infected in BJAB cells assessed as reduction in viral replication incubated for 3 days by qRT-PCR analysi |
CHEMBL4680252 |
| Norovirus |
EC50 |
= |
6400.0 |
nM |
Antiviral activity against Norovirus infected in human HG23 cells |
CHEMBL4814022 |
| Unchecked |
CC50 |
> |
300000.0 |
nM |
Cytotoxicity against human HG23 cells |
CHEMBL4814022 |
| ADMET |
Ratio CC50/EC50 |
= |
47.0 |
|
Selectivity index, ratio of EC50 for antiviral activity against Norovirus infected in human HG23 cells by visible analysis to CC50 for human HG23 cells |
CHEMBL4814022 |
| ADMET |
Activity |
= |
60.0 |
% |
Toxicity in rat assessed as animal survival at 15 to 30 mg/kg, iv measured for 7 days |
CHEMBL5150000 |
| Unchecked |
IC50 |
= |
11200.0 |
nM |
Inhibition of DENV RNA polymerase |
CHEMBL5150000 |
| Unchecked |
IC50 |
= |
19300.0 |
nM |
Inhibition of DENV RNA-dependent RNA polymerase activity |
CHEMBL5150000 |
| Dengue virus 1 |
EC50 |
= |
2900.0 |
nM |
Antiviral activity against DENV-1 RNA-dependent RNA polymerase infected in African green monkey Vero cells assessed as reduction in viral replication incubated for 2 days by qRT-PCR analysis |
CHEMBL5150000 |
| Dengue virus 2 |
EC50 |
= |
2800.0 |
nM |
Antiviral activity against DENV-2 RNA-dependent RNA polymerase infected in African green monkey Vero cells assessed as reduction in viral replication incubated for 2 days by qRT-PCR analysis |
CHEMBL5150000 |
| Dengue virus 3 |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against DENV-3 RNA-dependent RNA polymerase infected in African green monkey Vero cells assessed as reduction in viral replication incubated for 2 days by qRT-PCR analysis |
CHEMBL5150000 |
| Dengue virus type 4 |
EC50 |
= |
2600.0 |
nM |
Antiviral activity against DENV-4 RNA-dependent RNA polymerase infected in African green monkey Vero cells assessed as reduction in viral replication incubated for 2 days by qRT-PCR analysis |
CHEMBL5150000 |
